MESO Mesoblast Pharma: Multiplikator Forward P/S

Mesoblast Limited (MESO) is implementing a strategy to bring innovative cell-based therapies to market, and on GURU.Markets, this linear chart of the forward P/S ratio demonstrates a long-term trend where the metric holds at 14.10. High production scalability potential at low costs is combined with flawlessly optimized cold-chain logistics, ensuring stable global distribution of biomedical products.

MESO mesoblast.com: Rasio rega marang prakiraan pendapatan ing interval 04.07.2022 - 13.11.2026

Rincian analitis perusahaan Mesoblast Limited

- rega pasar lan target rega analis:

Bagan rega Mesoblast|MESO - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar Mesoblast Pharma|MESO - Nilai Total Perusahaan

- statistik nilai buku emiten:

Aset Bersih saben Siji Saham Mesoblast|MESO - Nilai Buku Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku mesoblast.com|MESO - Total Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Utang marang Ekuitas Mesoblast Limited|MESO - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Mesoblast Limited|MESO - Tanggungan utang kumulatif perusahaan|Utang marang nilai buku Mesoblast Pharma|MESO - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Mesoblast|Rasio cepet mesoblast.com

- data bathi bisnis lan rasio investasi:

MESO - Asil keuangan resik|Bathi sing dikarepake Mesoblast Limited|MESO - Koefisien rega marang bathi|Pangali Forward P/E Mesoblast Corp|MESO - Kapitalisasi marang bathi resik kanthi nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Mesoblast Pharma|MESO - Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|Bathi resik saben saham (EPS TTM) Mesoblast|MESO - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan mesoblast.com|MESO - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Mesoblast Limited

- indikator pendapatan dodolan lan penghasilan bisnis:

MESO - Dodolan perusahaan|Prakiraan volume dodolan Mesoblast|MESO - Rega marang dodolan|Rasio rega marang prakiraan pendapatan Mesoblast Pharma

Analisis umum perusahaan:Mesoblast (MESO)

The forward P/S multiple determines the investment attractiveness of Mesoblast Limited (MESO) by comparing current market capitalization with expected revenue, which helps identify the risk of asset overvaluation if forecasts are not met. This chart reflects market expectations regarding the commercialization of developments, which for a non-cyclical biotech business depends not on macroeconomic factors, but exclusively on the success of clinical trials for unique cellular products.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Lineage Cell Therapeutics, Inc. LCTX|Surrozen Inc (SRZN) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Cryo-Cell International Inc - Multiplikator Forward P/S|FBLG: Rasio rega marang prakiraan pendapatan|Longeveron Inc. (LGVN) - Rasio rega marang prakiraan pendapatan|BRTX (BioRestorative Therapies, Inc.) - Rasio rega marang prakiraan pendapatan|CELZ (Creative Medical Technology Holdings, Inc.) - Multiplikator Forward P/S